Elastic: A Phase Ib Study of Eltrombopag and Azacitidine in Patients with High Risk Myelodysplastic Syndromes and Related Disorders

Trial Overview and Summary

The aim of this clinical trial is to find out the safe dose (also called the maximum tolerated dose) of a drug called Eltrombopag when used in combination with Azacitidine in patients with Myelodysplastic Syndromes (MDS) and some types of Acute Myeloid Leukaemia (AML) and Chronic Myelomonocytic Leukaemia (CMML).

Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible

Chief Investigator:  Dr Alexander Sternberg
Sponsor:  University of Birmingham
Funders:  TAP, Bloodwise
Disease Site:  AML, MDS
Trial Type:  Clinical Trial of an Investigational Medicinal Product
Status:  Open
UKCRN Study ID: (if applicable)  14761
Open to new sites?  No
Recruitment start date:  27-Nov-2014
Anticipated Recruitment end date  30-Sep-2016
CRCTU Trial Management Team:  Haematology
Trial E-mail Address:  elastic@trials.bham.ac.uk

Trial Protocol

Please Note:

Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to CancerHelp website.

Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.

More Information

Please Note:

CancerHelp (Cancer Research UK) - Elastic trial